Treatment
Denosumab clinical trials
We’re tracking 26 recruiting studies that include Denosumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06938152RecruitingPhase 4
Comparing two bone-strengthening drug schedules for osteoporosis
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
TaipeiAges 50–90 - NCT07028268RecruitingPhase 2
Testing a new drug for bone metastases from solid tumors
This trial tests a new drug called SHR-2017 for people with solid tumors that have spread to the bones. The study aims to see if the drug can help manage pain and other effects of bone metastases.
Guangzhou, GuangdongAges 18 years+ - NCT04608630RecruitingPhase 2
Preventing bone loss in ICU patients with anti-bone drugs
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
Sydney, New South WalesAges 50 years+ - NCT05966064RecruitingPhase 4
Denosumab for adult fibrous bone lesions with ongoing pain
This trial studies denosumab to reduce pain and active bone disease in adults with fibrous dysplasia / McCune-Albright syndrome. You may be eligible if your FD/MAS is causing persistent pain and has signs of active bone turnover, despite adequate pain treatment.
LeidenAges 18 years+ - NCT06524960RecruitingPhase 1/Phase 2
Denosumab for Preserving Insulin in Type 1 Diabetes
This study tests if denosumab, a drug normally used for bone health, can help preserve your body's own insulin production in type 1 diabetes. It might slow the loss of insulin-making cells, helping you maintain better blood sugar control over time.
Birmingham, AlabamaAges 18–50 - NCT07034391RecruitingPhase 2
PD-1 inhibitor with denosumab and chemo for advanced lung cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
Shenyang, LiaoningAges 18–75 - NCT07271771RecruitingPhase 4
Denosumab for muscle and insulin in diabetes
This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.
AarhusAges 40 years+ - NCT07283887RecruitingPhase 4
Romosozumab and Denosumab for Postmenopausal Osteoporosis
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
Douliu, TaiwanAges 50–80 - NCT07406685RecruitingPhase 4
Comparing two bone medicines after stopping denosumab
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
TaipeiAges 50–85 - NCT06513624RecruitingPhase 1
ETC-159 plus pembrolizumab for advanced ovarian cancer
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Singapore, SingaporeAges 21–99 - NCT06643780RecruitingPhase 4
Denosumab for muscle loss in older adults with osteoporosis
This study tests whether a drug called Denosumab, which is used to treat bone loss, can also help improve muscle strength and mass in older adults who have both osteoporosis and sarcopenia. If you qualify, you would receive the drug and be monitored over time to see if it helps your bones and muscles.
Hong KongAges 65 years+ - NCT06164795Recruiting
Next steps after strong bone-building therapy
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
AthensAges 50–85 - NCT03755193RecruitingPhase 2
Testing another osteoporosis medicine after 2 years of denosumab
This study looks at how well and how safely another osteoporosis medicine works for people who have already taken denosumab for 2 years. It may help find the best next step to strengthen bones and lower fracture risk after denosumab.
Matsumoto, NaganoAges 20–120 - NCT03921060RecruitingPhase 4
Check osteoporosis markers in people with cystic fibrosis
This study looks for signs (markers) of bone thinning—called osteoporosis—in people with cystic fibrosis. Your participation may help researchers understand how osteoporosis develops in CF and whether a bone-strengthening medicine like denosumab could help, since some participants may need that medication.
Dallas, TexasAges 18–64 - NCT03958565Recruiting
Study how targeted drugs affect bone tumors in lung cancer
This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.
Aurora, ColoradoAges 18–100 - NCT04547348RecruitingPhase 3
Denosumab for healing an acute Charcot foot in diabetes
This Phase 3 trial tests whether denosumab can improve healing and outcomes for people with an acute Charcot foot caused by diabetes-related nerve problems. You may be able to join if your Charcot foot is recently diagnosed and you meet specific safety and lab requirements.
AalborgAges 18–80 - NCT05590949Recruiting
Study of bone problems after stopping breast cancer medicines
This observational study looks at bone complications in post-menopausal women with breast cancer after stopping denosumab and an aromatase inhibitor. It may help doctors better understand who is at risk for bone weakening and fractures after these medicines are stopped.
Basking Ridge, New JerseyAges 18 years+ - NCT05866029Recruiting
Prevention and treatment study for new brittle bone fractures
This study looks at ways to prevent and treat “brittle bone” refractures after a recent fracture in people with osteoporosis. If you’ve had a new hip, spine, or other bone fracture, the trial may test strategies to lower the chance of another fracture.
BeijingAges 45–90 - NCT06118905RecruitingPhase 4
Osteoporosis medication to preserve muscle in seniors
This study tests whether an osteoporosis medication can help preserve muscle strength in older adults who live in senior facilities. It's for people age 65+ with fragile bones or low bone density who are at risk for falls and fractures.
Pittsburgh, PennsylvaniaAges 65 years+ - NCT06357741Recruiting
Desuzumab for knee osteoarthritis
This study tests a new medicine called Desuzumab for knee osteoarthritis. It looks at whether the medicine can help reduce pain and improve joint function.
Wuhan, HubeiAges 45–75 - NCT06374459RecruitingPhase 1/Phase 2
Zunsemetinib and capecitabine for breast cancer with bone spread
This trial tests a new drug called zunsemetinib combined with the chemotherapy capecitabine for people with hormone receptor-positive, HER2-negative breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer.
Westwood, KansasAges 18 years+ - NCT06728462Recruiting
Calcium supplement study for postmenopausal women with osteoporosis
This study tests a new form of calcium (amorphous calcium carbonate) to see if it can improve bone density in postmenopausal women with osteoporosis. It may offer an alternative for women who cannot or choose not to take other osteoporosis medications.
Kaohsiung CityAges 60–90 - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06767150RecruitingPhase 4
Bone treatment after stopping denosumab for osteoporosis
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
AmiensAges 18 years+
What Denosumab is being studied for
Conditions with recruiting Denosumab studies.
Common questions
- Are there clinical trials studying Denosumab?
- Yes. Clin2 currently lists 26 recruiting studies that include Denosumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Denosumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Denosumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Denosumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.